Columbus Venture Partners announces the exit of Syngoi Technologies, a biotechnology company (CDMO) originated, developed and scaled from within the venture capital firm itself, and backed by its Columbus Life Science Fund II and Columbus Life Science Fund III. The acquisition has been carried out by the U.S.-based company Artis BioSolutions, a leading international platform in the development and manufacturing of advanced therapies.
The transaction represents a significant milestone for both Columbus Venture Partners and the Spanish biotech ecosystem: a bioindustrial project born in Spain that becomes part of a leading global platform, validating a value-creation model based on differentiated science, industrialisation and international scale-up.
In the words of the founders of Columbus Venture Partners, Javier García and Damià Tormo,
“This exit reinforces the purpose of our organisation. We do not only invest in companies; we originate strategic bioindustries capable of integrating into leading global platforms. Syngoi Technologies is the result of transforming differentiated science into industrial infrastructure from Europe with international impact.”
From foundational science to global bioindustrial infrastructure
Syngoi Technologies (Basque Country, 2021) has developed in recent years its own enzymatic synthetic DNA platform, designed to address one of the key structural challenges in the gene and cell therapy industry: the efficient, scalable and cost-effective production of critical inputs. Its integration into the Artis BioSolutions ecosystem will accelerate the transition towards more resilient, industrialised and global supply models.
From Columbus Venture Partners, the company was conceived not only as a scientific investment, but as a strategic industrial infrastructure, supporting its technological definition, operational scale-up and international positioning. The acquisition by Artis BioSolutions consolidates this vision and places Syngoi’s technology at the heart of the global advanced therapies value chain.
International integration with industrial roots in Bilbao
The transaction reinforces the industrial and global nature of the project while preserving its territorial roots. Syngoi Technologies will maintain and expand its scientific and industrial base in Bilbao, preserving the team, technological capabilities and GMP-ready facilities. This decision contributes to the consolidation of the Basque capital as an innovation hub within Artis BioSolutions’ international footprint and as a European biotech pole.
In parallel, Syngoi’s technology will be deployed in the United States through Landmark Bio, integrating synthetic DNA manufacturing with advanced development and therapy production capabilities, and accelerating its adoption at industrial scale.
“Syngoi’s technology provides an industrial response to a critical need in the advanced therapies market: ensuring the supply of high-quality synthetic DNA at scale and with operational efficiency,” says Julen Oyarzábal, CSO of Syngoi Technologies and Partner at Columbus Venture Partners.
An exit that accelerates the next phase of growth
For the Syngoi team, the transaction marks the beginning of a new phase of industrial scale-up and global adoption.
“Integration into Artis BioSolutions allows us to take this technology to a new dimension, providing it with industrial scale, operational robustness and global reach, with the aim of turning it into a reference standard for the next generation of advanced therapies,” highlights José Vicente Pons, CEO of Syngoi Technologies.
For his part, Brian Neel, co-founder and CEO of Artis BioSolutions, notes that
“This acquisition and partnership will enable our clients to move away from fragmented and costly models, integrating innovative synthetic DNA solutions within a more efficient, resilient and global industrial platform.”
The Columbus model: science that scales, value that crystallises
Alongside Columbus Venture Partners, Syngoi Technologies has been backed by specialised investors such as Buenavista—through its BV Healthcare Growth fund—and the Japanese pharmaceutical company Asahi Kasei Life Science, further reinforcing the attractiveness of the project and of the Spanish biotech ecosystem for international capital.
This exit clearly reflects the Columbus Venture Partners model: identifying differentiated science, transforming it into strategic industrial infrastructure, and connecting it with global leaders to maximise its economic, industrial and social impact.
Syngoi Technologies is an example of how, from Spain and from the Basque Country, it is possible to build critical bioindustrial assets for the global advanced therapies value chain.
